ZENA, a Vancouver-based AI drone, Drone as a Service (DaaS), enterprise software, and quantum computing company, carries unusually thin Wall Street coverage. Only two analysts publish price targets, and both were issued the same day. Maxim Group's Matthew Galinko maintained a Buy rating on June 8, 2026 while cutting his target to $5.00 from $7.00. On the same date, Litchfield Hills Research's Barry Sine initiated coverage with a Buy rating and a $4.00 target.
Averaging those two figures produces a central target of $4.50, within a narrow $4.00-to-$5.00 range. Both calls are bullish, but the lack of a Hold or Sell view means there is no meaningful dispersion to weigh. It is also important to note the timing: these targets were set before the stock's steep multi-month decline, and third-party trackers explicitly caution that targets "may not have had time to catch up." Investors should treat the $4.50 figure as the average of two June 2026 targets rather than a current, actively revised consensus. I also checked this using Tickeron’s AI Pattern Search Engine to compare historical moves in similar thinly covered names.
At a latest verified price near $0.55, ZENA shares have fallen roughly 85% over the past year, within a 52-week range of about $0.54 to $5.17. Reaching $4.50 would require a gain of approximately 720% — a very large move by any standard. Notably, the $4.50 target sits below the stock's 52-week high, underscoring how far the shares have retreated.
The path toward that target would require the market to re-rate a fast-growing but deeply unprofitable company. ZenaTech reported first-half 2026 revenue up 425% year over year, with preliminary third-quarter revenue guided to $9.5–$10.5 million. Yet it also posted a first-half net loss of roughly $34.8 million, meaning valuation rests on revenue growth and future profitability rather than current earnings. A sustained move higher would likely depend on continued DaaS momentum, progress in defense contracts, and evidence that losses and dilution are being brought under control.
ZenaTech's growth story is genuine at the top line. Its Drone as a Service segment contributed about 93% of revenue, supported by dozens of acquisitions of land-survey and inspection businesses being modernized with proprietary drone technology. The company has also pursued defense opportunities, including Blue UAS certification efforts, a counter-UAS platform, and a November 2026 memorandum of understanding with Rattler Medical to develop a drone-based battlefield blood-delivery system. Inclusion in the Russell 3000 Index in June 2026 added institutional visibility. If the company can convert these initiatives into recurring, higher-margin revenue, the case for a much higher valuation could strengthen.
The obstacles are substantial. ZenaTech remains loss-making, with negative EPS and significant cash burn as it integrates acquisitions and scales drone manufacturing. In October 2026 it expanded its at-the-market equity offering to $150 million, creating meaningful dilution risk that could continue to pressure the share price. Coverage is minimal, and the existing targets predate the sharp decline, so they may not reflect current fundamentals. Finally, the stock's persistent downward trend and deteriorating technical picture suggest investors are currently prioritizing profitability and cash generation over growth. One thing that stands out after reviewing the technicals with Tickeron’s AI Real Time Patterns is the lack of near-term reversal signals.
The most durable technical context is the 52-week range of roughly $0.54 to $5.17. The stock's all-time high territory near $5.17 now sits well above every current analyst target, while the low near $0.54 acts as a critical support level. After three consecutive down sessions in early November, the shares bounced from near the $0.56 area, and a first test of any recovery would be reclaiming the $0.70 level from early November. There is no near-term technical evidence of a base sufficient to support a move toward $4.50.
Analyst price targets generally reflect a roughly 12-month research horizon, though the two ZenaTech targets were published in June 2026 and have not been revised since. Investors should watch upcoming quarterly results and EPS revisions closely, along with any updates to the at-the-market offering and share count. Key items include DaaS acquisition closings and integration, progress on Blue UAS certification, defense procurement developments, and whether revenue growth begins translating into narrower losses. Any analyst target changes, upgrades, or downgrades would be especially significant given the extremely thin coverage.
In my research process, I frequently use Tickeron’s AI Daily Buy/Sell Signals to monitor volatile, thinly covered names like ZENA. The tool applies artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical behavior and market shifts. For a stock with limited analyst attention, it helps identify trend changes more efficiently than manual review alone, allowing me to stay on top of momentum without constant chart watching.
Can ZenaTech reach $4.50? The target — the average of two June 2026 analyst calls at $4.00 and $5.00 — implies a roughly 720% gain from the current price near $0.55, a very large move that would require both a dramatic recovery in sentiment and tangible progress on profitability. The supporting case rests on exceptional revenue growth and an expanding drone-services and defense pipeline, while the counterweights are persistent losses, dilution, and analyst targets that predate the stock's collapse. With only two covering analysts and stale targets, the $4.50 figure should be viewed as directional context rather than a near-term expectation. What happens next will hinge on earnings, cash burn, and whether management can convert growth into sustainable economics.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ZENA declined for three days, in 144 of 158 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ZENA entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for ZENA just turned positive on November 16, 2026. Looking at past instances where ZENA's MACD turned positive, the stock continued to rise in 12 of 14 cases over the following month. The odds of a continued upward trend are 86%.
Following a +9.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZENA advanced for three days, in 69 of 82 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ZENA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.558) is normal, around the industry mean (16.188). P/E Ratio (-0.383) is within average values for comparable stocks, (45.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.427) among similar stocks. P/S Ratio (4.342) is also within normal values, averaging (103.301).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ZENA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZENA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ComputerCommunications